Development and Validation of a Simple, Sensitive, Selective and Stability-Indicating RP-UPLC Method for the Quantitative Determination of Ritonavir and Its Related Compounds

被引:15
作者
Koppala, Srinivasarao [1 ,2 ]
Panigrahi, Bibhuranjan [1 ]
Raju, S. V. N. [1 ]
Reddy, K. Padmaja [1 ]
Reddy, V. Ranga [1 ]
Anireddy, Jaya Shree [2 ]
机构
[1] Dr Reddys Labs Ltd, Analyt Res & Proc Dev Integrated Prod Dev Operat, Qutubullapur 500072, Andhra Pradesh, India
[2] JNT Univ, Ctr Chem Sci & Technol, Hyderabad 500085, Andhra Pradesh, India
关键词
PERFORMANCE LIQUID-CHROMATOGRAPHY; PROTEASE INHIBITORS INDINAVIR; HUMAN PLASMA; SAQUINAVIR; NELFINAVIR; AMPRENAVIR; EFAVIRENZ; LOPINAVIR; MS/MS;
D O I
10.1093/chromsci/bmu097
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A simple, sensitive, selective and reproducible stability-indicating ultra-performance liquid chromatographic method was developed for the quantitative determination of degradation products and process-related impurities of Ritonavir in a pharmaceutical dosage form. Chromatographic separation was achieved on a polar embedded Waters Acquity BEH Shield RP18 (100 3 2.1 mm, 1.7 mm) column thermostated at 50 degrees C under gradient elution by using a binary mixture of potassium dihydrogen phosphate (0.01 M, pH 3.5) and acetonitrile at a flow rate of 0.5 mL/min. Chromatogram was monitored at 240 nm using a photodiode array detector. The drug and its related impurities are eluted within 20 min. To prove the stability-indicating power of the method, the drug was subjected to hydrolytic (acid, alkaline and water), oxidative, photolytic and thermal stress conditions. The unknown degradants were identified by the LC-MS-MS method, which revealed protonated molecular ion peaks [M + H](+) at m/z 551.40 for hydrolytic degradants, and m/z 737.60 and m/z 753.40 for photolytic degradants. A plausible mechanism for the formation of degradation and process impurities was proposed. The performance of the method was validated according to the International Conference on Harmonization guidelines.
引用
收藏
页码:662 / 675
页数:14
相关论文
共 25 条
[1]   Quantification of plasma and intracellular levels of the HIV protease inhibitor ritonavir by competitive ELISA [J].
Akeb, F ;
Ferrua, B ;
Creminon, C ;
Roptin, C ;
Grassi, J ;
Nevers, MC ;
Guedj, R ;
Garraffo, R ;
Duval, D .
JOURNAL OF IMMUNOLOGICAL METHODS, 2002, 263 (1-2) :1-9
[2]   Determination of saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography and the analytical error function [J].
Albert, V ;
Modamio, P ;
Lastra, CF ;
Mariño, EL .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2004, 36 (04) :835-840
[3]  
[Anonymous], RIT MON US PHARM, P5991
[4]  
[Anonymous], 2005, Validation of analytical procedures: Text and methodology Q2 (R1)
[5]  
[Anonymous], 2005, RIT MON PHARM, P498
[6]  
Behera A., 2011, Chronicles of Young Scientists, V2, P161, DOI [10.4103/2229-5186.90894, DOI 10.4103/2229-5186.90894]
[7]  
Chiranjeevi K, 2011, INT J PHARM SCI RES, V2, P596
[8]   LC method for studies on the stability of lopinavir and ritonavir in soft gelatin capsules [J].
Donato, E. M. ;
Dias, C. L. ;
Rossi, R. C. ;
Valente, R. S. ;
Froehlich, P. E. ;
Bergold, A. M. .
CHROMATOGRAPHIA, 2006, 63 (9-10) :437-443
[9]   Analysis of ritonavir in plasma/serum and tissues by high-performance liquid chromatography [J].
Granda, BW ;
Giancarlo, GM ;
von Moltke, LL ;
Greenblatt, DJ .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 1998, 40 (04) :235-239
[10]  
International Conference on Harmonisation, 2003, STAB TEST NEW DRUG S